Stephan Grupp, MD, PhD from Children's Hospital of Philadelphia, Philadelphia, PA discusses his research into pediatric acute lymphoid leukemia (ALL). In a relapsed or refractory setting 93% of the patients entered complete remission (CR) when treated with CTL019, a chimeric antigen receptor T-cell (CAR T-cell). Furthermore, many of these patients were able to stay in remission. Dr Grupp also discussed toxicity associated with these engineered T-cell, specifically cytokine release syndrome. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.